Education
About Us
Working with TipRanks
Follow Us
PainChek Ltd (AU:PCK)
ASX:PCK
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$34.49M
Enterprise ValueAU$31.79M
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring SaaS Revenue ModelPainChek’s revenue is primarily subscription/licensing and implementation fees, a recurring model that supports predictable revenue streams, higher lifetime value, and scalable unit economics. Over 2–6 months this durability aids retention, upsell and margin leverage as adoption deepens.
Accelerating Revenue And Improving Gross MarginTop-line acceleration with an improving gross margin signals improving product-market fit and unit economics. If sustained, these trends reduce the revenue required to break even and provide a path to absorb fixed costs, supporting longer-term profitability as scale grows.
No Debt On The Balance SheetHaving no debt materially reduces fixed financial obligations and bankruptcy risk, giving management flexibility to fund growth via equity or strategic partnerships. This structural strength improves survivability while cash burn is addressed.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow of ~-6.8M materially erodes runway and forces reliance on external capital. Over months this constrains investment in sales, regulatory work or product development and elevates refinancing and dilution risk.
Deep And Persistent UnprofitabilityA net margin near -228% indicates operating costs far exceed current revenues, implying structural cost or scale issues. Without significant revenue scale-up or substantial cost restructuring, profitability remains distant and risks ongoing capital raises.
Deteriorating Shareholders' EquityNegative shareholders’ equity reflects accumulated losses and weakens the capital cushion. This deterioration limits financing options, raises creditor and investor scrutiny, and increases the probability of dilutive equity issuance to shore up the balance sheet.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.17 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$34.49M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 174 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PCK Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$60.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-8647.54%
Trailing 12-Months
Asset Growth
-48.60%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---